Invivyd Inc. Announces Positive In Vitro Data for PEMGARDA and VYD2311 Against Dominant COVID-19 Variant XFG
Reuters
Aug 19
Invivyd Inc. Announces Positive In Vitro Data for PEMGARDA and VYD2311 Against Dominant COVID-19 Variant XFG
Invivyd Inc. has announced new positive in vitro neutralization data for its investigational monoclonal antibodies, PEMGARDA® (pemivibart) and VYD2311, against the currently dominant XFG variant of SARS-CoV-2. These results demonstrate that both antibodies maintain their neutralizing activity, confirming the stability of the epitopes they target. Invivyd's data also show consistent efficacy against other circulating variants, such as NB.1.8.1 ("Nimbus"), LF.7.9, and LP.8.1. The company plans to provide this data to the U.S. Food and Drug Administration (FDA) imminently, with the expectation that it will be included in the PEMGARDA Fact Sheet for Healthcare Providers. The results underscore the potential of Invivyd's antibodies to offer continued clinical activity against evolving SARS-CoV-2 variants.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9514390-en) on August 18, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.